Continuous variables evaluated in major depressive disorder (MDD) meta-analysis. Hedges g (Cohen effect size with small sample correction) is shown for each structure, with 95% confidence intervals. The effect size is positive when the structure is larger in patients with MDD compared with controls and negative when the structure is smaller in MDD patients. The number of studies included in each meta-analysis is indicated with each structure. CSF indicates cerebrospinal fluid; CT, computed tomography; DWMH, deep white matter hyperintensities; GM, gray matter; L, left; MRI, magnetic resonance imaging; PFC, prefrontal cortex; PVH, periventricular hyperintensities; R, right; ScGMH, subcortical gray matter hyperintensities; and WM, white matter.
Categorical variables evaluated in major depressive disorder (MDD) meta-analysis. Odds ratio is shown for each type of hyperintensity, with 95% confidence intervals. Odds ratio larger than 1 indicates that the hyperintensity is more common in patients with MDD compared with control group members. The number of studies included in each meta-analysis is indicated with each type of hyperintensity. GM indicates gray matter; MRI, magnetic resonance imaging; and WM, white matter.
Customize your JAMA Network experience by selecting one or more topics from the list below.
Kempton MJ, Salvador Z, Munafò MR, et al. Structural Neuroimaging Studies in Major Depressive Disorder: Meta-analysis and Comparison With Bipolar Disorder. Arch Gen Psychiatry. 2011;68(7):675–690. doi:10.1001/archgenpsychiatry.2011.60
Although differences in clinical characteristics exist between major depressive disorder (MDD) and bipolar disorder (BD), consistent structural brain abnormalities that distinguish the disorders have not been identified.
To investigate structural brain changes in MDD using meta-analysis of primary studies; assess the effects of medication, demographic, and clinical variables; and compare the findings with those of a meta-analysis of studies on BD.
The MEDLINE, EMBASE, and PsycINFO databases were searched for studies from January 1, 1980, to February 2, 2010.
Two hundred twenty-five studies that used magnetic resonance imaging or x-ray computed tomography to compare brain structure in patients with MDD with that of controls were included in an online database, and 143 that measured common brain structures were selected for meta-analysis.
Twenty-five variables, including demographic and clinical data, were extracted from each study, when available. For the meta-analysis, mean structure size and standard deviation were extracted for continuous variables, and the proportion of patients and controls with an abnormality in brain structure was extracted for categorical variables.
Compared with the structure of a healthy brain, MDD was associated with lateral ventricle enlargement; larger cerebrospinal fluid volume; and smaller volumes of the basal ganglia, thalamus, hippocampus, frontal lobe, orbitofrontal cortex, and gyrus rectus. Patients during depressive episodes had significantly smaller hippocampal volume than patients during remission. Compared with BD patients, those with MDD had reduced rates of deep white matter hyperintensities, increased corpus callosum cross-sectional area, and smaller hippocampus and basal ganglia. Both disorders were associated with increased lateral ventricle volume and increased rates of subcortical gray matter hyperintensities compared with healthy controls.
The meta-analyses revealed structural brain abnormalities in MDD that are distinct from those observed in BD. These findings may aid investigators attempting to discriminate mood disorders using structural magnetic resonance imaging data.
Epidemiologic and treatment studies have confirmed differences in clinical characteristics between major depressive disorder (MDD) and bipolar disorder (BD). Major depressive disorder, compared to BD, has a higher lifetime prevalence (16% vs 2%),1,2 has an older median age at onset (32 vs 25 years),3 and is associated with a lower number of depressive episodes.4 Antidepressants are the most commonly prescribed medication for MDD5; mood stabilizers, such as lithium, are the most frequently prescribed treatment for BD.6 However, despite these differences, consistent biomarkers distinguishing the disorders have been elusive.
It is not clear whether changes in brain structure differentiate MDD from BD or whether common abnormalities are present in both disorders. Reviews7,8 of imaging studies have attempted to identify structural differences specific to each disorder in a qualitative fashion. In addition, meta-analyses, which quantitatively summarize research findings, have revealed evidence of structural abnormalities in patients with BD9-11 and MDD12-16 compared with healthy individuals. However, to our knowledge, meta-analytical methods have not been used to establish whether the identified abnormalities distinguish the disorders.
In the present study, we conducted a comprehensive meta-analysis of studies on brain structural changes in patients with MDD compared with controls and examined the specificity of these abnormalities by comparing the findings with those found in patients with BD. In the meta-analysis of MDD imaging studies, we increased both the number of included publications and brain regions by a factor of 2 compared with the largest previous meta-analysis.13 Using data from a meta-analysis of studies on BD,9 we made direct statistical comparisons between structural measures from each disorder while attempting to control for differences in study characteristics such as scanning parameters and patient demographics. Previous meta-analyses12,13 of studies on patients with MDD most consistently report hippocampal volumetric reduction; we applied meta-regression techniques to investigate the effect of clinical variables on hippocampal volume. Finally, we provide an online database of 225 MDD structural imaging studies, listing 25 variables from each study, when available (http://www.depressiondatabase.org). The database is presented as an open-access wiki,17 enabling other researchers to add studies.
The study was divided into 3 parts: (1) the construction of a database of 225 studies investigating structural abnormalities in MDD, (2) a meta-analysis comparing patients with MDD with controls from a subgroup of 143 studies, and (3) a statistical comparison of structural abnormalities between patients with MDD and those with BD.
The inclusion criteria for the database required peer-reviewed studies that measured brain structure using x-ray computed tomography (CT) or magnetic resonance imaging (MRI) in patients with MDD and a control group. The MEDLINE, EMBASE, and PsycINFO databases were searched from January 1, 1980, to February 2, 2010, using a combination of relevant expanded subject headings and free-text searches; detailed search terms are given in our wiki database. A total of 3960 records of unique publications were initially examined; we excluded case studies, reviews, studies that had not used standard diagnostic criteria, studies that combined MDD with BD patients in a single group, duplicate publications, and investigations using voxel-based morphometry (VBM) because the results of these studies cannot be included in a traditional meta-analysis. We did not include epidemiologic studies that diagnosed depression based on cutoffs of rating scales or considered antidepressant use a proxy for MDD diagnosis because the agreement between these measures and standard diagnostic criteria is questionable.18 Two hundred twenty-five publications fulfilled the inclusion criteria and were included in the database.
The following data were recorded from each study when available: number of MDD patients and controls, mean age, number of males and females in the patient and control groups, and the diagnostic classification system used. Mean age of the patient at onset of the disease and mean Hamilton Scale for Depression (HAM-D)19 score were also recorded. The HAM-D scale was chosen over other depression rating scales because it is the most commonly reported. For current medication, we recorded the number of patients who were described as drug free (not necessarily medication naive), as well as the number using mood stabilizers, antipsychotics, and antidepressants, including the class of antidepressant (selective serotonin reuptake inhibitor, tricyclic, monoamine oxidase inhibitor, or other). Information on current medication use was extracted from the publications directly; because data regarding prior exposure to medication were rarely presented, this information was not systematically collected. For each study, we recorded all brain structures or abnormalities measured, whether the measurement was MRI or CT based, slice thickness, and field strength of the MRI scanner.
The majority of variables in the database were not normally distributed; therefore, correlations were assessed using Spearman rank correlation (SPSS 15.0; SPSS Inc, Chicago, Illinois).
To ensure no bias in selecting brain regions/abnormalities for the meta-analysis, we recorded every structure or abnormality investigated in the 225 studies. As with previous meta-analyses, exact anatomic definitions of individual structures varied across studies. For a given structure, some studies reported left and right measurements separately, and other studies reported the combined measurement. For studies that reported measures for the left and right volumes but not the total, we determined the mean and standard deviation for the total volume, using a reported method13 that requires an estimate of the correlation coefficient between the left and right volumes. This coefficient was set as 0.8, although it was varied in the sensitivity analysis (described in the “Sensitivity Analysis” subsection of the “Methods” section). To ensure that the meta-analysis was sufficiently powered, brain regions were included if there were 3 or more independent studies that reported a mean and SD in both the control and patient groups (continuous measures), and abnormalities were included if there were 3 or more independent studies that reported the number of patients and controls with the abnormality (categorical measure). From the 225 studies in the database, there were a total of 324 different brain regions examined; however, only 63 regions were examined by 3 or more studies, and these were entered in the meta-analysis. The total number of studies included in the meta-analysis was 143; many studies in the database did not examine 1 or more of the 63 identified regions. The studies in the meta-analysis included 9 publications that used CT measures of total lateral ventricle volume (analyzed as a subgroup), and all other brain structures were examined using MRI.
For continuous outcome measures, Hedges g was used, which is the Cohen effect size with a correction for bias from small sample sizes.20 The percentage difference effect size is also provided to aid biological interpretation of the data.21 The majority of studies report absolute volume measures; however, some report volumes as ratios of the entire brain or cross-sectional area measures. All such measurements have been included in the meta-analysis; however, because combining measures may increase heterogeneity, an additional analysis was carried out with volume measures only (see “Sensitivity Analysis” subsection of the “Methods” section). For categorical outcome measures, the odds ratio was used. Outcome measures were recorded from each study and were independently checked to ensure accuracy. For a given brain structure, if 2 or more studies by the same research group reported similar patient or control demographics, we contacted the authors of those studies to determine whether there was overlap in the sample and, if this was the case, included only the largest relevant study. A total of 150 measures from 52 studies were excluded for this reason. A meta-analysis for each brain structure was performed (using the metan command in Stata 9.2, 2006; StataCorp LP, College Station, Texas). Outcome measures were combined using a random-effects inverse-weighted variance model.22 Because the meta-analyses examined a large number of regions and are susceptible to type I errors, results that survive Bonferroni correction for multiple comparisons (corrected for 63 regions, P < .0008) are indicated.
A minority of imaging studies presented measures from subgroups of patients. For these studies, we entered the subgroups in the meta-analysis as if they were separate studies and, in each case, the number of individuals in the control group was considered the sample size of the control group divided by the number of patient subgroups. This method has been used in a previous meta-analysis.9 If studies reported on males and females separately, we entered the results as if they were from 2 separate studies, a technique adopted by another previous meta-analysis.23
To test for between-study heterogeneity, the Cochran Q test statistic was calculated.24 The I2 statistic, which is equal to the percentage of total variation across studies as the result of heterogeneity, was also calculated to aid interpretability of between-study heterogeneity.25
The effect of small-study bias (which may include publication bias) was investigated for regions in which the pooled effect size revealed a significant group difference between MDD patients and controls and when at least 5 studies were included in the meta-analysis to ensure that the test was sufficiently powered. Small-study bias was assessed using the Egger regression test.26
The number of brain regions and clinical variables included in the database allows a potentially high number of correlations to be examined, which may lead to type I errors. Thus, the analysis was limited to the effect of clinical variables on total hippocampal volume. We selected this region because of the robust evidence of volumetric reduction in MDD12,13 and because many studies have measured this structure, ensuring adequate statistical power. A random effects meta-regression was implemented (metareg command in Stata 9.2) to examine age at onset, HAM-D score, percentage of patients using antidepressants, number of depressive episodes, and patient age. In addition, we combined studies that directly compared the same MDD subgroups (eg, depressed vs remitted patients) in a supplementary meta-analysis. Finally, we determined whether the reduction in hippocampal volume remained when the meta-analysis was restricted to the following MDD patient groups: no comorbid anxiety disorders, no history of alcohol/substance abuse or dependence, first episode, adolescents, adults, and elderly patients.
To test how robust the results were to variations in the meta-analysis method, the effect of the following was examined: (1) percentage difference in the patient and control mean volumes as an outcome measure for continuous data (calculation of this effect size and the effect size variance has been described in more detail in previous meta-analytical studies21,23); (2) excluding studies that reported continuous data as areas, lengths, or ratios rather than absolute volume; and (3) setting the correlation coefficient between the left and right regional volumes as 0.1, 0.5, and 1.
Two meta-analytical approaches may be taken to examine differences between MDD and BD: (1) meta-analysis of studies directly comparing the same brain structure in patients with MDD vs those with BD or (2) indirect analysis comparing the pooled effect size from studies comparing MDD patients vs controls with that from studies comparing BD patients vs controls. We adopted the second approach, which has the advantage of including more studies and brain structures because there are very few direct comparisons. Thus, to compare the results from the MDD meta-analysis with those of a previous meta-analysis of BD studies,9 we combined the effect sizes from BD patients vs controls with MDD patients vs controls (effectively, a meta-analysis of studies on patients with affective disorder) and performed a stratified meta-analysis using a z test to compare across the 2 disorders. To match the method exactly, the BD meta-analysis was reanalyzed, using the technique of combining left and right brain structural measures adopted in the present MDD meta-analysis. To reduce the number of comparisons, we focused on brain regions that were significantly different from those of controls (before Bonferroni correction) in either the MDD or BD meta-analysis.
We adopted a 2-stage process to ensure that significant differences between the groups that were identified in the stratified meta-analysis were not the result of variations in patient demographics or scanning parameters rather than MDD or BD diagnosis. First, for each brain structure, we examined whether the following summary variables were significantly different between MDD and BD studies, using an independent-samples t test: percentage of patients who were female, medication free, using antidepressants, using neuroleptics, and using mood stabilizers; mean patient age; scanner magnetic field strength; and slice thickness. Second, when a significant difference was identified between BD and MDD studies for those variables, a meta-regression was performed separately in MDD and BD studies to examine the effect of the variable on the given brain structure.
Demographic and clinical data from the database are reported, followed by results from the MDD meta-analyses and comparison with the BD meta-analysis.
Details from 225 studies that included a total of 9533 patients with MDD and 8846 controls were entered into the database. Table 1 summarizes the variables recorded. The classification systems used for defining MDD were DSM-IV (156 studies); DSM-III-R (46 studies); DSM-III (13 studies); International Classification of Diseases, Ninth Revision or International Classification of Diseases, Tenth Revision (5 studies); Research Diagnostic Criteria27 (4 studies); and Chinese Classification of Mental Disorders28 (1 study). Two hundred eight studies used MRI and 17 studies used CT imaging. Among MRI studies, 81% used a 1.5-T scanner; 11% used a lower field strength and 6% used a higher field strength. The mean (SD) slice thickness was 9.0 (1.0) mm in CT studies and 2.8 (2.1) mm in MRI studies. There was evidence that studies were recruiting larger numbers of patients over time (R = 0.21; P = .002) and that the number of studies per year was increasing (R = 0.94; P < .001).
The 143 studies included in the meta-analysis29-171 are listed in Table 2. Compared with controls, patients with MDD had larger lateral ventricular and cerebrospinal fluid (CSF) volumes and smaller volumes of the total caudate, putamen, globus pallidus, thalamus, hippocampus, frontal lobe, orbitofrontal gray matter, and gyrus rectus (Figure 1 and Table 3). The pituitary gland was increased in volume, with borderline significance (P = .054). Patients with MDD had moderately increased rates of MRI signal hyperintensities, but this was dependent on the measurement technique used. When hyperintensity rating scales were used, periventricular hyperintensities were increased (Figure 1 and Table 3); when categorical classification was used (patient classified as having hyperintensities or no hyperintensities), subcortical gray matter hyperintensities were increased (Figure 2 and Table 4). The differences that survived Bonferroni correction (P < .0008) were increased lateral ventricle and CSF volume and decreased hippocampal and gyrus rectus volume (Table 3). No small-study bias was detected in any of the brain regions identified in this paragraph (all P > .11).
Because outliers may have a disproportionate effect on meta-regression analysis, 2 outliers113,167 were removed before investigating the effect of clinical variables on total hippocampal volume (effect sizes of outliers, −3.8 and −2.2; effect size range of the remaining 35 studies, −1.3 to +0.4; and pooled effect size after 2 studies were excluded, −0.40). There was no significant effect of age at onset (23 studies, P = .75), HAM-D score (18 studies, P = .58), percentage of patients using antidepressants (22 studies, P = .61), number of depressive episodes (20 studies, P = .25), or patient age (35 studies, P = .54) on the difference in hippocampal volume between patients and controls. For each meta-regression performed, the heterogeneity of the included studies remained significant (I2 > 28%). In terms of subgroups, patients with MDD in remission had a significantly larger hippocampal volume compared with patients who were currently depressed (4 studies, effect size, 0.34; 95% confidence interval, 0.02-0.67; P = .04); there was no significant difference in volume between patients with remitted MDD and controls (5 studies, P = .25). In addition, there was no significant difference in hippocampal volume between patients with first episode vs multiple episodes (4 studies, P = .32) or patients with early- vs late-onset depression (3 studies, P = .24). The significant reduction in hippocampal volume remained when the meta-analysis was limited to first-episode studies (6 studies; effect size, −0.22; P = .04); studies that excluded patients with a comorbid anxiety disorder (10 studies; effect size, −0.39; P < .001); and studies that excluded patients with a history of drug abuse/dependence or substance abuse/dependence (6 studies; effect size, −0.32; P < .001), adults (mean age, 20-60 years; 22 studies; effect size, −0.43; P < .001), and elderly patients (60-75 years; 8 studies; effect size, −0.34; P < .001). Although the effect size was similar to that of other subgroups, there was no significant reduction of hippocampal volume in adolescent patients (12-19 years; 5 studies; effect size, −0.35; P = .11).
When percentage change was used as the effect size for continuous data, there was a reduction in the volume of the right orbitofrontal cortex and an increase in deep white matter hyperintensities as measured by rating scales in patients with MDD, and the decrease previously observed in the globus pallidus became a trend. If ratio, length, and area measurements were excluded, lateral, ventricle measures using CT imaging could not be included because all studies reported a ventricle to brain ratio measure; no other changes were noted. There was no change in the results when the correlation coefficient between left and right regions was set to 0, 0.5, or 1.
Nine regions included in both the MDD and BD meta-analyses showed significant differences from controls, allowing a comparison to be made (Table 5). Six of these regions differed between MDD and BD. Compared with BD patients or controls, patients with MDD had significantly reduced volumes of the caudate, putamen, globus pallidus, and hippocampus. Compared with MDD patients or controls, patients with BD had significantly reduced cross-sectional areas of the corpus callosum and increased rates of deep white matter hyperintensities. Compared with controls, both MDD and BD patients showed ventricular dilation and increased rates of subcortical gray matter hyperintensities, but there was no significant difference between the patient groups.
When we examined differences in study characteristics between BD and MDD investigations for each of the 6 brain regions identified in the previous paragraph, there were significant differences in terms of patient age (5 regions), sex (3 regions), and medication use (5 regions), but no significant differences in terms of scanner field strength or slice thickness. From the follow-up meta-regression analyses, there was no significant effect of patient age, sex, or medication use on any of the 6 regions in either BD or MDD studies. One exception was patient age in BD studies, in which increased age was associated with increased hippocampal volume compared with matched controls (P = .001).
In patients with MDD compared with controls, we identified increased lateral ventricle and CSF volume; reduced volume of the basal ganglia, thalamus, hippocampus, frontal lobe, orbitofrontal cortex, and gyrus rectus; and increased rates of periventricular and subcortical gray matter hyperintensities. Currently depressed MDD patients had smaller hippocampal volumes vs those with remitted MDD. Within mood disorders, basal ganglia and hippocampal volume reductions appear to be specific to MDD, and reduced corpus callosum cross-sectional area and increased rates of deep white matter hyperintensities appear to be specific to BD.
In MDD patients compared with controls, we found bilateral reductions in hippocampal volume (−5%) as reported by previous meta-analyses,12,13,174 and also showed a strong significant trend for increased pituitary volume (P = .054, 5%). These findings may provide evidence for the involvement of the hypothalamic-pituitary-adrenal axis in MDD. The anterior pituitary produces adrenocorticotropic hormone, and it is conceivable that an increased volume of the pituitary may be associated with increased adrenocorticotropic hormone production. A primary role of adrenocorticotropic hormone is stimulation of the adrenal cortex, which responds by producing glucocorticoids. There is strong evidence that glucocorticoid levels are increased in MDD, and prolonged high levels may damage hippocampal neurons.175 A small number of studies measured the adrenal gland in MDD; these were not included in our meta-analysis because only 2 (not meeting our criterion of 3) measured this structure in a group including only patients with MDD. However, because of the weight of evidence supporting the involvement of the hypothalamic-pituitary-adrenal axis, we entered these studies into an additional meta-analysis (not previously reported). The 3 case-control studies comprised 1 MRI study that evaluated 3 BD patients with 32 MDD patients as a single group176 and 2 CT studies of MDD patients.177,178 Adrenal volume was significantly increased compared with controls (effect size, 0.81; 95% confidence interval, 0.45-1.16; P < .0001), providing further evidence of an association between MDD and hypothalamic-pituitary-adrenal axis abnormalities. The finding that hippocampal volume was significantly smaller in patients with a depressed compared with remitted state raises the possibility that reductions in hippocampal volume may normalize during remission, and it is tempting to speculate that this may be the result of neurogenesis in the dentate gyrus.179 A longitudinal study performing scans on the same patients during depression and after recovery would be an effective way of examining these putative changes in more detail. Although we did not detect an association between antidepressant use and hippocampal volume, there is growing evidence that antidepressants may upregulate neurogenesis. Malberg et al180 reported that chronic antidepressant therapy increased neurogenesis in rats and an antipsychotic medication had no effect. More recently, a postmortem study181 reported that depressed patients who had been treated with antidepressants had an increased number of neural progenitor cells in the dentate gyrus compared with untreated patients or controls. In previous meta-analyses, Videbech and Ravnkilde12 reported that increased duration of illness was associated with smaller right hippocampal volume, and McKinnon et al14 did not find hippocampal reduction in first episodes of MDD. Conversely, we did not find an association with duration of illness and determined that hippocampal volume reduction was present in patients at first episode. However, in our analysis, the effect size in first-episode studies (0.22) was numerically less than that in all studies combined (0.47), suggesting that the volumetric reduction may be less marked in the early stages of the illness.
Four frontal regions were smaller in MDD patients compared with controls. Although we could not confirm that the subgenual prefrontal cortex was reduced in volume in MDD, it is possible that functional,59,182 rather than structural, abnormalities are of greater prominence in this region. The most significant effect sizes were observed in the orbitofrontal cortex and gyrus rectus. Deficits of prefrontal cortical activation in MDD are relatively consistent in functional neuroimaging studies,183 and postmortem studies184 have reported reduced neuronal and glial density in the dorsal lateral and orbitofrontal cortex. We confirm the findings of a previous meta-analysis,13 which reported reduced volume of the caudate and putamen in patients with MDD, but we also found significant volume reductions of the globus pallidus. Although the basal ganglia have primarily been linked to motor function, the ventral striatum, including the nucleus accumbens, has been strongly associated with limbic systems, particularly reward networks.185
Although increased rates of hyperintensities are considered an established finding in MDD, particularly in older patients,186 our meta-analysis showed only modest increases compared with healthy controls. The reported effect sizes in this meta-analysis were smaller than those in 2 earlier meta-analyses16,187 of depression studies. Our meta-analysis included only studies on patients with MDD; however, both previous meta-analyses included studies that evaluated MDD and BD patients as a single group,188-190 which may have inflated the effect size. Indeed, our study indicates that patients with BD have more than a 2-fold increase in rates of deep white matter hyperintensities compared with MDD patients (Table 5).
We excluded reports on VBM from the meta-analysis; however, a qualitative review of these studies partially supports our findings. In 12 VBM studies that examined gray matter volume, the most consistent findings were hippocampal volume reduction (7 studies)191-197 and volumetric reductions within the frontal lobe (7 studies).191,192,194-196,198,199 Changes shown with VBM that were not found in our meta-analysis included reductions within the amygdala (4 studies)194-196,200 and cingulate cortex (6 studies),193-195,199-201 although 1 study198 found an increase in volume.
Based on findings from a large number of independent studies in the meta-analysis comparison, MDD is associated with reductions in basal ganglia and hippocampal volume, and BD is more strongly associated with white matter abnormalities, specifically deep white matter hyperintensities and reduced corpus callosum area. In terms of similarities, both disorders showed ventricular enlargement and increased rates of subcortical gray matter hyperintensities. The positive association between patient age and hippocampal volume in the BD sample reinforces the identified difference in hippocampal volume between patients with MDD and those with BD; if studies on BD had recruited older patients in the same way as MDD studies did, the difference would have been greater. The larger extent of gray matter volume reductions in MDD was surprising, given that BD is considered a more chronic illness and is associated with an earlier age at onset2 and more episodes of major depression compared with MDD.4 The finding that white matter abnormalities were more strongly associated with BD than MDD was also unexpected; however, this is supported in a review by Mahon et al,202 who reported evidence of abnormal white matter in BD from studies using a variety of neuroimaging techniques in addition to neuropathologic and genetic studies. Because studies of twins have shown that there are both overlapping and distinct genetic risk factors for BD and MDD,203 it is possible that the unique genetic factors for each disorder are associated with the distinct structural abnormalities identified in this meta-analysis. Twin studies have also shown that environmental factors have a stronger influence in MDD than in BD.204 It is possible that the reduction in hippocampal volume observed in MDD but not BD is linked to stressful life events playing a more prominent role in the development of MDD.
Although the case-control meta-analysis is statistically highly powered, the meta-regression analysis of clinical variables lacks power and may be prone to type I and type II errors. In the comparison between MDD and BD, we limited the analysis to regions that were significantly different from controls in either the MDD or BD meta-analysis. This strategy reduces the number of comparisons and associated type I errors; however, it is possible that brain regions that distinguish the disorders were overlooked. Although we attempted to take into account differences in medications between the groups, it was not possible to account for this entirely because of the limited information reported in studies. A previous meta-analysis of BD studies9 and other studies205,206 have shown that use of lithium may increase gray matter volume, and it is possible that lithium may be masking abnormalities that would have been observed if patients with BD were not using this medication. The results from a long-term prospective study207 suggest an approximate 1% conversion rate from MDD to BD every year, which complicates the comparison of MDD and BD studies. Therefore, it is possible that the differences in brain structure between MDD patients who do not convert and BD patients are more pronounced than the differences reported in this study.
In conclusion, in this meta-analysis, we have shown robust structural brain abnormalities in MDD and particular changes in brain volume that may distinguish MDD from BD. These results may aid imaging studies aiming to use structural MRI data to distinguish patients with MDD from those with BD. Further studies may reveal whether these abnormalities are a risk factor for developing MDD, when they first occur, and whether they are predictive of treatment response.
Correspondence: Matthew J. Kempton, MSc, PhD, Department of Neuroimaging, PO89, Institute of Psychiatry, King's College London, De Crespigny Park, London SE5 8AF, England (email@example.com).
Submitted for Publication: April 22, 2010; final revision received September 28, 2010; accepted November 30, 2010.
Author Contributions: Dr Kempton had full access to all the data in the study and takes responsibility for the integrity of the data and the accuracy of the data analysis.
Financial Disclosure: None reported.
Funding/Support: The authors acknowledge financial support from the National Institute for Health Research (NIHR) Specialist Biomedical Research Centre for Mental Health award to the South London and Maudsley NHS Foundation Trust and the Institute of Psychiatry, King's College London, and the ongoing support of the Wellcome Trust and Engineering and Physical Sciences Research Council toward the Medical Engineering Centre within King's College London. Dr Kempton was also supported by a Wellcome Trust Value in People Award.
Role of Sponsors: The sponsors of the study had no role in the design or conduct of this study; in the collection, management, analysis, and interpretation of the data; or in the preparation, review, or approval of the manuscript.
Additional Contributions: Magaly Cermeño, BEng, independently verified data entered into the meta-analysis.
Create a personal account or sign in to: